Sunday, August 29, 2021 12:20:10 PM
Analyzing the investment case for buying stock in the high-flying life sciences and diagnostics company.
Motley Fool
by Lee Samaha
Aug 4, 2021
https://www.fool.com/investing/2021/08/04/is-danaher-a-buy-in-a-post-pandemic-world/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Key Points
The pandemic has enhanced the company's long-term growth potential.
Current trading continues to exceed expectations.
Non-COVID-19 related revenue is back in growth mode.
Life science and diagnostics company Danaher (NYSE:DHR) is one of the big winners from the COVID-19 pandemic. Its diagnostic tests help detect the coronavirus, and its life sciences tools help medical bodies research and develop vaccines and therapies for it.
That said, what happens to the company's growth rate after the pandemic is over? Are investors in the stock about to be left holding a stock trading on a high valuation that's just about to see earnings growth prospects deteriorate?
Three reasons Danaher can keep on delivering
I think there's reason to believe that Danaher can keep growing at a very healthy clip, even in a post-pandemic environment.
Current earnings momentum is robust across all its businesses, COVID-19 related and non-COVID-19 alike.
Management's guidance for non-COVID-19 related revenue growth in 2021 has been upgraded and demonstrates underlying strength in the business.
The pandemic has strengthened the company's core business and growth prospects.
Strong earnings momentum
The company recently delivered its second-quarter earnings, and it managed to sail past management's previous guidance. For example, management had previously forecast second-quarter core revenue growth would come in within the mid-20% range, but it came in at 31.5%. As such, management upgraded its expectation for full-year core revenue growth from "high teens" to "approximately 20%."
As you can see below, the life sciences and diagnostics segments continue a powerful run, boosted by the pandemic (more on that in a moment), and the environmental and applied solutions (EAS) business is also back in growth mode. For reference, life sciences contributed $2.3 billion of operating profit in the first half compared to $1.3 billion from diagnostics and $565 million from EAS.
EAS is a collection of water quality and product ID businesses. During the earnings call, CEO Rainer Blair noted that both business platforms grew strongly in the quarter as the reopening of the economy increased sales and order rates as customers were investing in "larger projects" again.
Non-COVID-19 growth is strong too
The burning question on everybody's lips is, what kind of growth rate can investors expect after the pandemic? To help answer it, Danaher's management breaks out its guidance into COVID-19 related revenue and its "base business." As noted earlier, the full-year core revenue growth guidance was raised to "approximately 20%."
Going into more detail on the matter, Blair said "We anticipate that COVID related revenue tailwinds will be an approximately 10% contribution to the core revenue growth rate, and in our base business, we now expect that core revenue will be up 10% for the full year, an increase from our prior expectation of high single-digit."
In other words, the ramp up in the guidance primarily comes down to an increase in the guidance from the base business. That bodes well for Danaher's post-pandemic growth prospects.
The pandemic has structurally enhanced Danaher's growth
This is a subtle and critical point to understand. It's not just that the pandemic provided a temporary boost to Danaher's prospects. In life sciences, the investment made worldwide in vaccine and therapeutic science to combat the coronavirus is likely to spill out into broader-based research that can benefit Danaher for years to come.
Meanwhile, Blair outlined that monoclonal antibody-based therapies in development have increased 50% "from just five years ago." Turning back to COVID-19, there's always the possibility that a third booster shot and wide-scale vaccination of children will provide a near-term boost to Danaher's sales.
Danaher has increased its installed base of diagnostic platforms by over 40% since the pandemic started. That's important because the diagnostics business works based on the "razor/razor blade" business model. In other words, more platform sales lead to more opportunities for Danaher to sell new tests into the installed base. For example, Blair pointed out that assays (tests) for sexual health and hospital-acquired infections were up 30% in the second quarter. Also, Danaher is continually working on new assays.
Danaher is ramping up capital spending from $790 million in 2020 to around $1.5 billion in 2021, partly to build on the growth in assay development and fuel growth in the Cytiva biopharma business bought from General Electric in 2020.
Is Danaher a buy?
The exciting thing about Danaher's valuation is that it trades on roughly the same enterprise value (market cap plus net debt)-to-earnings before interest, taxation, depreciation, and amortization (EBITDA) valuation as it did before the pandemic started.
Therefore, if you believe in relative valuations, then Danaher is an attractive stock because the pandemic has enhanced its long-term growth potential. On the other hand, it's still a pretty hefty valuation to trade on, and cautious investors might want to wait for a dip to buy into a very attractive company.
<<<
Recent DHR News
- Danaher Schedules Third Quarter 2024 Earnings Conference Call • PR Newswire (US) • 09/19/2024 08:30:00 PM
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership • PR Newswire (US) • 09/17/2024 12:30:00 PM
- Danaher Announces Quarterly Dividend • PR Newswire (US) • 09/10/2024 08:15:00 PM
- Danaher Confirms Third Quarter and Full Year 2024 Guidance • PR Newswire (US) • 09/04/2024 08:30:00 PM
- Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C. • PR Newswire (US) • 08/26/2024 09:30:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration • PR Newswire (US) • 07/25/2024 01:00:00 PM
- Danaher Reports Second Quarter 2024 Results • PR Newswire (US) • 07/23/2024 10:00:00 AM
- Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development • PR Newswire (US) • 07/17/2024 11:30:00 AM
- Danaher Releases 2024 Sustainability Report • PR Newswire (US) • 07/16/2024 11:30:00 AM
- Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening • PR Newswire (US) • 07/11/2024 11:30:00 AM
- Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer • PR Newswire (US) • 07/09/2024 07:00:00 AM
- Danaher Schedules Second Quarter 2024 Earnings Conference Call • PR Newswire (US) • 06/24/2024 08:30:00 PM
- Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics • PR Newswire (US) • 06/19/2024 11:30:00 AM
- Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer • PR Newswire (US) • 06/05/2024 11:00:00 AM
- Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis • PR Newswire (US) • 05/09/2024 11:00:00 AM
- Danaher to Present at Bank of America Securities Healthcare Conference • PR Newswire (US) • 05/07/2024 08:45:00 PM
- Danaher Announces Quarterly Dividend • PR Newswire (US) • 05/07/2024 08:15:00 PM
- Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry • PR Newswire (US) • 05/03/2024 01:06:00 PM
- Danaher Reports First Quarter 2024 Results • PR Newswire (US) • 04/23/2024 10:00:00 AM
- Danaher Schedules First Quarter 2024 Earnings Conference Call • PR Newswire (US) • 03/21/2024 08:15:00 PM
- Danaher to Present at TD Cowen Health Care Conference • PR Newswire (US) • 02/27/2024 09:15:00 PM
- Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets • PR Newswire (US) • 02/22/2024 09:15:00 PM
- Danaher Announces Quarterly Dividend • PR Newswire (US) • 02/21/2024 09:15:00 PM
- Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development • PR Newswire (US) • 02/05/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM